{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010933","form_type":"8-K","ticker":"RKDA","cik":"0001469443","company_name":"Arcadia Biosciences, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.132367+00:00","generated_at":"2026-06-17T09:10:06.298396+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcadia Biosciences FY2022 revenue up 47% to $9.96M; net loss per share improves to $25.65 from $27.56","bullets":["Total revenues $9.956M, up 47% YoY; Q4 revenue $1.0M, down 54% YoY.","Operating expenses $28.771M, down 32% YoY; cash used in operations $13.977M, down 46%.","Net loss attributable to common stockholders $15.376M ($25.65/share) vs $14.660M ($27.56/share) in 2021.","GoodWheat pasta launched in Q2 2022, reached 1,200+ stores within 7 months; AHA Heart-Check certified.","CEO Stan Jacot appointed in Q1 2022; Project Greenfield 3-year plan for profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010933","json":"https://secwatch.observer/filing/0000950170-23-010933.json","markdown":"https://secwatch.observer/filing/0000950170-23-010933.md","text":"https://secwatch.observer/filing/0000950170-23-010933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469443/000095017023010933/0000950170-23-010933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469443/000095017023010933/rkda-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:10:06.298396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bcb5bb1e273c675c720a59b1349cf7ea42122462","claim":"Arcadia Biosciences, Inc. reported financial results for fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On March 30, 2023 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017023010933/0000950170-23-010933-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}